TG Therapeutics sells Briumvi for multiple sclerosis.
TG Therapeutics, Inc. (TGTX) is expected to report earnings on Monday, November 2, 2026, before the open. Estimated release time 07:22 ET. Consensus EPS estimate is $0.36.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | Jun 2026 qtr | $0.31 | $0.05 | — | $240.34M |
| 2026-05-06 | Mar 2026 qtr | $0.23 | $0.14 | — | $204.92M |
| 2026-02-27 | Dec 2025 qtr | $0.35 | $0.16 | — | $192.57M |
| 2025-11-05 | Sep 2025 qtr | $0.24 | $2.69 | — | $161.71M |
| 2025-08-08 | Jun 2025 qtr | $0.32 | $0.19 | — | $141.15M |
| 2025-05-09 | Mar 2025 qtr | $0.18 | $0.03 | — | $120.86M |
| 2025-03-03 | Dec 2024 qtr | $0.08 | $0.16 | — | $108.19M |
| 2024-11-07 | Sep 2024 qtr | $0.03 | $0.03 | +0.0% | $83.88M |
TGTX has beaten consensus EPS in 1 of its last 1 scored quarters.
See TGTX on the live calendar →